The round was led by 8090 Industries with participation from new and existing investors. Using the power of plants, Tiamat provides animal-free recombinant growth factors with a highly flexible technology, at a fraction of their cost and with a reduced carbon footprint. The new funds will accelerate product validation in the cellular agriculture and regenerative medicine markets and establish strategic partnerships with industry leaders.

Along with 8090 Industries, who led this seed-extension round, True ventures, Social impact capital, Cantos, Portfolia, Alexandria, Siddhi Capital, Sara Murray, Seed folio, Sustainable Food Ventures and Exponential Impact also participated in this financing round. This brings the total fund raised by Tiamat Sciences to $5.4M.

Tiamat Sciences is reinventing recombinant proteins to fuel the next generation of biotech companies across cellular agriculture, regenerative medicine, vaccine production, and more. Using the power of plants, Tiamat provides animal-free recombinant proteins at a fraction of their cost with a reduced carbon footprint. The team is on track to become a fast-growing supplier of recombinant proteins.